Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Research Report on China's Measles, Mumps and Rubella (MMR) Vaccine Industry, 2018-2022 - Research and Markets

Research and Markets
Posted on: 22 Dec 17

The "Research Report on China's Measles, Mumps and Rubella (MMR) Vaccine Industry, 2018-2022" report has been added to Research and Markets' offering.

Measles, mumps and rubella are acute respiratory infectious diseases caused by viruses, all of which can be spread through droplets coming from respiratory tracts. Children and teenagers are high risk groups of diseases. Breakout of epidemics among groups will not only result in harms to their health but also have a direct impact on normal teaching orders and even cause social panics.

Measles has the highest incidence rate and mortality rate, posing extremely huge threats to children's health. People infected with measles usually have clinic manifestations like fever, rashes and cold. Although rubella and mumps exhibit slight clinic symptoms and favorable prognosis, mumps sometimes brings about serious complications, such as boys with secondary orchitis and girls with secondary ovaritis, further leading to sterility and infertility when they grow up. If women are infected with measles at the early stage of pregnancy, there is a possibility of abortion and foetal malformation.

The researcher analyzes that despite reduced incidence rates of measles, rubella and mumps in China in recent years, there is still a big gap between the actual incidence rate of measles and the targeted incidence rate set by WHO, which is required to be less than 1/ 1 million people.

Research suggests that the sales volume of MMR vaccines exhibited a fluctuating trend in China between 2013 and 2017. This fluctuation is mainly attributed to factors such as government policies and market demand. In 2016, the sales volume of MMR vaccines exceeded 70 million.

The MMR vaccine is gradually taking up the market shares of other vaccines because of its good effect, preventing three types of infectious diseases.

Companies Mentioned

  • Beijing Bio-Institute Biological Products Co., Ltd.
  • Beijing Minhai Biological Products Co., Ltd.
  • Beijing Tiantan Biological Products Co., Ltd.
  • Changchun Keygen Biological Products Co., Ltd.
  • Shanghai Institute of Biological Products Co., Ltd.
  • Wuhan Institute of Biological Products Co., Ltd.

Key Topics Covered:

1 Development Environment of China Vaccine Industry, 2015-2018

2 Overview of China MMR Vaccine Market, 2013-2017

3 Analysis on China MMR Vaccine Market, 2013-2017

4 Major MMR Vaccine Manufacturers in China, 2015-2018

5 Prospect of China MMR Vaccine Market, 2018-2022

For more information about this report visit https://www.researchandmarkets.com/research/cnxbgj/research_report

View source version on businesswire.com: http://www.businesswire.com/news/home/20171222005175/en/

Business Wire
www.businesswire.com

Last updated on: 22/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.